eli lilly glp-1 FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and hormone receptors - New clinical trial data from
Description
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
adults will have obesity by 2035a burden that doesn't affect all races and ethnicities equally
Click here to see which areas are affected.
Mounjaro and Ozempic both help control blood sugar and promote weight loss in people with diabetes
